CAR‐T cells targeting different molecules such as CD19, CD20, CD22, and BCMA have been developed and investigated for the administration of leukemia, lymphoma, and MM.3, 4, 5, 6, 7. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.